Subscribe free

HPB & Spleen ·

Monitoring MPD Growth Crucial in IPMN Management

Dynamic changes in main pancreatic duct (MPD) diameter are key in predicting malignancy risk for patients with MPD-involved IPMN.

  • In a study of 168 patients, 17.8% developed malignancy over a median of 4 years, with an annual incidence of 4.5%.
  • An MPD growth rate of ≥ 2 mm/year emerged as the strongest predictor, with a staggering odds ratio of 33.0 (p < 0.001).

Focus on MPD monitoring can guide timely surgical interventions, enhancing patient outcomes.

  • Cumulative malignancy incidences were 7.7% at 2 years, 14.3% at 4 years, and 14.9% at 6 years.

Journal Article by Choi SJ, Kim TH (…) Yang DW et 13 al. in J Gastroenterol Hepatol

© 2025 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

read the whole article in J Gastroenterol Hepatol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →